PGEN
NASDAQ · Biotechnology
Precigen Inc
$7.72
+0.02 (+0.26%)
Financial Highlights (FY 2026)
Revenue
11.19M
Net Income
-290,031,366
Gross Margin
50.2%
Profit Margin
-2,588.2%
Rev Growth
-28.9%
D/E Ratio
4.46
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 50.2% | 50.2% | 42.3% | 42.3% |
| Operating Margin | -1,141.1% | -1,027.0% | -7.4% | -9.4% |
| Profit Margin | -2,588.2% | -2,458.8% | -8.5% | -8.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 11.19M | 15.73M | 411.38M | 421.12M |
| Gross Profit | 5.62M | 7.90M | 173.84M | 177.96M |
| Operating Income | -127,706,939 | -161,563,459 | -30,534,477 | -39,472,830 |
| Net Income | -290,031,366 | -366,921,885 | -34,816,902 | -35,997,358 |
| Gross Margin | 50.2% | 50.2% | 42.3% | 42.3% |
| Operating Margin | -1,141.1% | -1,027.0% | -7.4% | -9.4% |
| Profit Margin | -2,588.2% | -2,458.8% | -8.5% | -8.6% |
| Rev Growth | -28.9% | -28.9% | +17.8% | -9.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.15B | 1.15B | 657.59M | 697.63M |
| Total Equity | 258.24M | 258.24M | 694.85M | 748.63M |
| D/E Ratio | 4.46 | 4.46 | 0.95 | 0.93 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -124,190,503 | -165,843,376 | -49,679,638 | -48,292,540 |
| Free Cash Flow | — | — | -21,385,787 | -28,685,035 |